<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815853</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCCGPS2</org_study_id>
    <nct_id>NCT01815853</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer</brief_title>
  <acronym>Neo-CRAG</acronym>
  <official_title>An Randomized, Multicenter, Open-label, Phase III Trial Comparing Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients With Locally Advanced Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Cancer Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Medical University Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with histologically confirmed gastric adenocarcinoma with locally advanced gastric
      cancer are randomized in a 1:1 ratio to receive neoadjuvant chemoradiotherapy with DT45Gy/25f
      plus three cycles of XELOX therapy or neoadjuvant chemotherapy alone using XELOX regimen
      following D2 gastrectomy and adjuvant chemotherapy for 3 cycles. The primary end point is
      disease free survival (DFS), and secondary end point is 5-year overall survival (OS),
      pathological complete remission (pCR) and treatment safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Literatures have shown that patitents with locally advanced gastric cancer could
      potentially benefit from neoadjuvant chemoradiotherapy, but whether this can improve
      patitents' outcome is still unclear.

      Patients and methods: In this study , patients with histologically confirmed gastric
      adenocarcinoma with pre-operative staging are cT3N2/N3M0, cT4aN+M0 and cT4bNanyM0, aged
      between 18-75 years old, with adequate organ function and having an Eastern Cooperative
      Oncology Group performance status score â‰¤2, are randomized in a 1:1 ratio to receive
      neoadjuvant chemoradiotherapy with DT45Gy/25f plus three cycles of XELOX therapy
      (Capecitabine 1000mg/m2, BID, D1-14; Oxaliplatin 130mg/m2 on day 1 for a 21-day cycle) or
      neoadjuvant chemotherapy alone using XELOX regimen following by D2 gastrectomy and adjuvant
      chemotherapy with same dosage of XELOX therapy for up to 3 cycles. The primary end point is
      disease free survival (DFS), and secondary end point is 5-year overall survival (OS),
      pathological complete remission (pCR) and treatment safety. The final study analytics are to
      be conducted at the end of the 5th year after the last patient's enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Neoadjuvant Chemoradiotherapy versus Neoadjuvant Chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>3-year DFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>5-year Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Remission</measure>
    <time_frame>Peri-operative period</time_frame>
    <description>pCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radical Resection Rate</measure>
    <time_frame>Peri-operative period</time_frame>
    <description>R0 Resection Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>Peri-operative period</time_frame>
    <description>Treatment safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neoadjuvant Chemoradiotherapy</intervention_name>
    <description>Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)</description>
    <arm_group_label>Neoadjuvant Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant Chemotherapy</intervention_name>
    <description>3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)</description>
    <arm_group_label>Neoadjuvant Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>R0 D2 Gastrectomy</intervention_name>
    <arm_group_label>Neoadjuvant Chemoradiotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant Chemotherapy</intervention_name>
    <description>3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)</description>
    <arm_group_label>Neoadjuvant Chemoradiotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consensus of the enrolled patients

          -  being able to receive oral drug

          -  from 18 to 75 years old

          -  proven to be primary adenocarcinoma of gastric cancer and pre-operative staging
             cT3N2/N3M0, cT4aN+M0, cT4bNanyM0,

          -  no prior other chemotherapy and/or radiation against the disease

          -  normal function of all other vital organs including heart,liver ,kidney and so on

          -  Eastern Cooperative Oncology Group performance status: 0~2

        Exclusion Criteria:

          -  history of other malignancy

          -  allergic reaction to capecitabine or oxaliplatin

          -  enrolled in other clinical trials

          -  abnormal GI tract function

          -  dysfunction of other organs

          -  pregnant or lactating females ,or refuse to receive contraception measures during
             chemotherapy

          -  other situations judged as not adaptive to the study by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-wei Zhou, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi-wei Zhou, M.D, Ph.D</last_name>
    <phone>0086-20-87343626</phone>
    <email>zhouzhw@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Wang, M.D, Ph.D</last_name>
    <phone>0086-20-87343910</phone>
    <email>wangwei@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wang, M.D, Ph.D</last_name>
      <phone>0086-20-87343910</phone>
      <email>wangwei@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Zhi-wei Zhou, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhou Zhiwei</investigator_full_name>
    <investigator_title>Director of Gastric Surgery</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Locally advanced gastric cancer</keyword>
  <keyword>Pathological complete response</keyword>
  <keyword>D2 gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

